The program targets organizations that require high-level multiplex IF capabilities but lack the internal capacity or specialized expertise to manage the entire workflow on-site. Clients can now outsource specific stages of their projects—from panel design and staining to imaging and data analysis—while utilizing Revolune’s adaptable staining technology. According to CEO Florian Leiss, the initiative provides a practical entry point for biopharma firms and research teams, allowing them to balance in-house development with external service support.

Each partner contributes distinct expertise to the ecosystem. CellCarta provides global precision medicine services with a focus on histopathology and regulatory-ready data. Concept Life Sciences offers end-to-end analytical support for drug discovery, while Propath UK specializes in spatial biology and complex proteomic workflows. This partner-led strategy represents a shift in Revolune’s commercial approach, moving beyond direct equipment sales to build a collaborative network that accelerates biomarker discovery and translational research.